Printer Friendly

INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES PRICING OF EURO-EQUITY FINANCING

 INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES PRICING
 OF EURO-EQUITY FINANCING
 TORONTO, Dec. 4 /PRNewswire/ -- International Murex Technologies Corporation (AMEX: MXX; TSE) today announced that it has priced the previously disclosed Euro-Equity financing at U.S.$11.25 per share.
 The financing, syndicated through an international group led by Deacon Barclays de Zoete Wedd Limited, is set to close on Dec. 19, subject to receipt of regulatory approvals.
 The net proceeds of the offering will be used by MXX to continue its ongoing acquisition program, including the proposed acquisition from the Wellcome Foundation Limited (WFL) of its diagnostics division, Wellcome Diagnostics, and for general working capital requirements. On Nov. 5, the company announced that it had entered into negotiations with WFL with respect to the proposed acquisition. The completion of these negotiations is subject to the company's satisfactory review of the business to be acquired, as well as negotiation and execution of definitive documentation.
 The U.S. Food and Drug Administration (FDA) has completed its final inspection of the manufacturing facility of the company's subsidiary, Murex Corporation in Norcross, Ga. Completion of the inspection occurred on Nov. 22. The company anticipates approvals of its Single Use Diagnostic Systems (SUDS) AIDS test by the FDA prior to month-end January 1992.
 Toronto-based MXX is an international medical diagnostic systems company dedicated to the development, manufacture and global marketing of cost-effective diagnostic tests for infectious diseases and products for the blood banking industry.
 -0- 12/4/91
 /CONTACT: C. Robert Cusick, president and chief executive officer, or Marcia M. Young of International Murex Technologies, 800-688-1332 or 416-408-4682/
 (MXX) CO: International Murex Technologies Corporation ST: Georgia, Ontario IN: MTC SU:


BN -- AT005 -- 9052 12/04/91 09:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 4, 1991
Words:282
Previous Article:TIGERA GROUP ANNOUNCES DIRECTORS' RESIGNATIONS
Next Article:PENTLAND GROUP PROPOSED SALE OF HOLDING IN REEBOK INTERNATIONAL
Topics:


Related Articles
INTERNATIONAL MUREX REPORTS NOTIFICATION OF 13-D FILING
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES EQUITY OFFERING
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES THIRD QUARTER RESULTS
INTERNATIONAL MUREX TECHNOLOGIES ANNOUNCES DOMINION BIOLOGICALS RECEIVES FDA NOTIFICATION OF FINAL SITE INSPECTION FOR NOVACLONE(TM) PRODUCTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES EXERCISE OF OPTION AND INCLUSION IN TSE 300 COMPOSITE INDEX
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION CLOSES EURO-EQUITY OPTION FOR NEW COMMON SHARES
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION ANNOUNCES COMPLETION OF THE PURCHASE OF WELLCOME DIAGNOSTICS
INTERNATIONAL MUREX PROMOTES J. DAVID THOLEN TO CHIEF EXECUTIVE OFFICER
INTERNATIONAL MUREX LICENSES TECHNOLOGY TO ABBOTT LABORATORIES
International Murex Reports First Quarter Earnings of $0.10 Per Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters